Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05364086 · ClinicalTrials.gov registry record

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by University of Rochester NCORP Research Base.

Active
Registry status
2,100
Enrollment target
20
Study locations

NCT05364086 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is active but no longer recruiting, run by University of Rochester NCORP Research Base. The registered enrollment target is 2,100 participants, above the 1,129-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (86% higher). The trial reports 20 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05364086, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is active but no longer recruiting, sponsored by University of Rochester NCORP Research Base.

ACTIVE NOT RECRUITING
Registry status
2,100 participants
Enrollment target
20
Study locations

Study Summary

This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • OTHER Electronic Health Record Review
  • OTHER Interview

Study Locations (20)

California

  • Kaiser Permanente-Anaheim - Anaheim
  • Kaiser Permanente-Deer Valley Medical Center - Antioch
  • Kaiser Permanente-Baldwin Park - Baldwin Park
  • Kaiser Permanente-Bellflower - Bellflower
  • Kaiser Permanente Dublin - Dublin
  • Kaiser Permanente-Fontana - Fontana
  • Kaiser Permanente-Fremont - Fremont
  • Kaiser Permanente-Fresno - Fresno
  • Kaiser Permanente South Bay - Harbor City
  • Kaiser Permanente-Irvine - Irvine
  • Kaiser Permanente Los Angeles Medical Center - Los Angeles
  • Kaiser Permanente West Los Angeles - Los Angeles
  • Kaiser Permanente-Modesto - Modesto
  • Kaiser Permanente-Oakland - Oakland
  • Kaiser Permanente-Ontario - Ontario
  • Kaiser Permanente - Panorama City - Panorama City
  • Kaiser Permanente- Marshall Medical Offices - Redwood City
  • Kaiser Permanente-Richmond - Richmond
  • Kaiser Permanente-Riverside - Riverside

Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro

Trial Details

FieldValue
Enrollment Target 2,100 participants
Start Date 2022-04-26
Est. Completion 2030-01-31

What the Registry Record Tells You About NCT05364086

The ClinicalTrials.gov registry entry for NCT05364086 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,129-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (86% higher). The listed sponsor is University of Rochester NCORP Research Base, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05364086 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT05364086 about?

NCT05364086 is a clinical study titled "An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study". This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patie...

What is the current status of trial NCT05364086?

This trial is currently active not recruiting. The enrollment target is 2,100 participants. The study started on 2022-04-26. Estimated completion is 2030-01-31.

What conditions does trial NCT05364086 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT05364086?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Electronic Health Record Review (OTHER), Interview (OTHER).

Who is sponsoring clinical trial NCT05364086?

This trial is sponsored by University of Rochester NCORP Research Base, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05364086 being conducted?

This trial has 20 study locations across Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.